Abstract
During periods of heavy exercise training and competition, lipid, protein, and nucleic molecules can become damaged due to an overproduction of reactive oxygen and nitrogen species (RONS) within the exercising organism. As antioxidants can prevent and delay cellular oxidative damage through removing, deactivating, and preventing the formation of RONS, supplementation with exogenous antioxidant compounds has become a commercialized nutritional strategy commonly adopted by recreationally active individuals and athletes. The following review is written as a critical appraisal of the current literature surrounding astaxanthin and its potential application as a dietary supplement in exercising humans. Astaxanthin is a lipid-soluble antioxidant carotenoid available to supplement through the intake of Haematococcus pluvialis-derived antioxidant products. Based upon in vitro and in vivo research conducted in mice exercise models, evidence would suggest that astaxanthin supplementation could potentially improve indices of exercise metabolism, performance, and recovery because of its potent antioxidant capacity. In exercising humans, however, these observations have yet to be consistently realized, with equivocal data reported. Implicated, in part, by the scarcity of well-controlled, scientifically rigorous research, future investigation is necessary to enable a more robust conclusion in regard to the efficacy of astaxanthin supplementation and its potential role in substrate utilization, endurance performance, and acute recovery in exercising humans.
Introduction
Reactive oxygen and nitrogen species (RONS) produced during exercise are recognized as fundamental stressors that can promote improvements in athletic performance and overall health (ā). To ensure that improvements are sustained, recreationally active individuals and athletes are required to manipulate the volume, intensity and frequency of each exercise bout over time (). During periods of heavy exercise training, a vast system of interrelated endogenous antioxidant compounds (i.e., superoxide dismutase, catalase, glutathione peroxidase) work together to ensure RONS production does not become detrimental (). Multifaceted in its function, this system can prevent and delay the oxidation of biomolecules through removing, deactivating and preventing the formation of RONS (, ). If exercise training becomes too vigorous, however, an excessive production of RONS can overwhelm the endogenous antioxidant defense system, causing a state of oxidative stress (). Consequently, lipid, protein and nucleic molecules may become damaged, with potentially detrimental impacts on normal physiological function (, ). The intake/ingestion of exogenous antioxidants has, therefore, become common practice in both recreationally active and athletic populations (). As essential non-enzymatic molecules, exogenous antioxidants have the potential to supplement the endogenous antioxidant defense system if adequately sourced from the diet (). An example of a potent antioxidant that can be sourced through either dietary intake or supplementation is the xanthophyll carotenoid, astaxanthin. Previously, astaxanthin has been suggested to enhance exercise metabolism, performance and recovery as a result of its potent antioxidant capacity (ā). Evidence to support this notion has been predominantly derived from studies using in vitro and in vivo animal models (ā, ). The focus of the following review is to, therefore, critically appraise the current literature surrounding astaxanthin and its potential application as a dietary supplement within exercising humans. Underlying mechanistic factors pertaining to exercise metabolism, performance and recovery will also be considered alongside the identification of present and future areas of research focus.
Astaxanthin
Astaxanthin (3,3ā²-dihydroxy-β, βā²-carotene-4,4ā²-dione) is a naturally occurring carotenoid found in marine species, such as microalgae, crustacea, fish and some birds (, ). Utilized in aquaculture, astaxanthin provides the characteristic reddish pigment to farm-raised salmon tissue (). Following the initial work of Kurashige et al. () and Miki (), however, an alternative use for astaxanthin as a potent antioxidant compound in both in vitro and in vivo systems has been suggested. As it is oxygenated (C40H52O4), astaxanthin is classified as part of the xanthophyll sub-species of the carotenoid family (), with its potency seemingly underpinned by its structure at a molecular level (, , , ). With a molecular mass of 596.84āgĀ·molā1, astaxanthin contains two β-ionone ring systems within its structure that are linked by a polyene chain and contain the oxygenated keto and hydroxyl moieties (). The presence of the polyene chain alongside each moiety enables astaxanthin to exert multiple antioxidant functions, namely in the scavenging and quenching of RONS within the phospholipid membrane as well as at the surface (, ).
Sources of Astaxanthin
As the human organism is unable to synthesize astaxanthin naturally, its uptake is dependent upon the dietary intake of foods, such as salmon, lobster, shrimp and crab (). Whilst current data regarding the dietary intake of astaxanthin are insufficient, it is estimated that more than 70% of salmon production worldwide is farm-raised where astaxanthin is utilized as a feeding additive (). If it is assumed that all dietary sources of seafood are obtained from aquaculture, it is estimated that the average European adult would consume between 0.8 and 2.0āmgĀ·dayā1 astaxanthin, with the higher percentile not expected to exceed intakes of 4.1āmgĀ·dayā1 (). Alternatively, the intake of astaxanthin is possible through regular dietary supplementation, with a typical intake of 4āmgĀ·dayā1 astaxanthin recommended across several brands of commercially produced astaxanthin products (). Existing as three separate stereoisomers [(3S, 3ā²S), (3R, 3ā²R), and (3R, 3ā²S)] (), the commercial applications of astaxanthin range from daily capsules and soft gels to energy drinks and powders (). Although the production of astaxanthin for aquacultural purposes can be sourced from a range of synthetic and natural sources, the only form currently commissioned for direct human consumption as a commercial product is the (3S, 3ā²S)-isomer (, ). As a result, recent endeavors have been made to improve the production of astaxanthin from natural sources, such as Haematococcus pluvialis, to ensure that demands for human applications can be achieved ().
Bioavailability of Astaxanthin
Primitive data are available from research that has quantified the uptake and elimination kinetics of astaxanthin in the plasma via high-performance liquid chromatography (ā). This method of analysis was utilized by Rüfer et al. () during the investigation of 28 healthy males over a 4-week period. Prior to study onset, astaxanthin concentrations were quantified as non-detectable, following which two randomized groups (nā=ā14 each group) consumed either 250āg of wild or aquacultured salmon daily, to obtain ~1.25āmgĀ·dayā1 astaxanthin (5āµg astaxanthinĀ·gā1 salmon flesh). Following 6ādays of consumption, astaxanthin concentrations reached a plateau of 33.7ā±ā16.2ānmolĀ·Lā1 (wild salmon) and 52.4ā±ā16.2ānmolĀ·Lā1 (aquacultured salmon), respectively, with concentrations reported to not significantly change for the remainder of the protocol (). It therefore appears that when the intake of astaxanthin is chronic, maximal concentrations can be achieved and maintained within the first week of intake, even when astaxanthin is obtained from different sources. This data, however, is collated from one study only, where astaxanthin was consumed as part of the diet, requiring a daily intake of 250āg salmon (). Future research should, therefore, aim to clarify the bioavailability of astaxanthin from a variety of different sources, including supplementation, with information regarding the elimination kinetics also of importance to understand how the availability of astaxanthin may diminish over time.
Currently, the European Food Safety Authority (EFSA) advise an acceptable daily intake (ADI) of 0.034āmgĀ·kgā1Ā·dayā1 astaxanthin (2.38āmgĀ·dayā1 in a 70-kg human) (, ). Despite this, pharmacokinetic data are available from studies that have issued acute doses of 40 and 100āmg, respectively (ā). Following the ingestion of an acute H. pluvialis-derived 40āmg capsule, maximal plasma concentrations of 55.2ā±ā15.0āµgĀ·Lā1 astaxanthin were recorded in eight healthy male participants (). In the same study, uptake was significantly enhanced if astaxanthin was ingested as one of three lipid-based formulations (nā=ā8 each group), with maximal plasma concentrations in the range of 90.1 and 191.5āµgĀ·Lā1 reported (). As a result, it is advised that astaxanthin should be consumed alongside the intake of dietary fats to ensure uptake can be optimized (). In comparison, increased maximal concentrations of 1.3ā±ā0.1āmgĀ·Lā1 and 0.28ā±ā0.12āmgĀ·Lā1 are reported in the plasma following an acute intake of 100āmg astaxanthin (, ). Although a high level of variance exists between the two studies, this may be explained by the low sample sizes (nā=ā3 each study), which should be addressed in future research (, ).
Additional information is also available regarding the pharmacokinetics of astaxanthin following acute supplementation regimes. Indeed, maximal blood astaxanthin concentration is observed between 8 and 10āh following the intake of 40āmg astaxanthin (nā=ā32) (), with similar times of 6.7ā±ā1.2āh (nā=ā3) and 11.5āh (nā=ā3) also observed following doses of 100āmg (, ). Furthermore, a half-life of 15.9ā±ā5.3āh is reported following a 40āmg dose (), with half-lives of 21ā±ā11 and 52ā±ā40āh reported following the intake of a 100āmg dose (, ). It therefore appears that the concentrationātime profile of astaxanthin is monophasic following ingestion and can be described as a one-compartment model. Future research should seek to replicate these findings in doses equivalent to those advocated by the EFSA (0.034āmgĀ·kgā1), as well as those available in commercial astaxanthin products (4āmg). In doing so, optimal dosing strategies can be developed and subsequently implemented for both chronic and acute methods of administration.
Mechanism of Action
In comparison to other popular phytochemicals, astaxanthin has previously been reported to possess a significantly greater antioxidant function (, , ), with its antioxidant activities quantified as 10-fold greater than other carotenoids, such as β-carotene, and 100-fold greater than α-tocopherol (vitamin E) (). In particular, astaxanthin seemingly holds an affinity for singlet oxygen and peroxyl radical intermediates (ā, ). Through a process of energy transfer, for example, astaxanthin is able to quench singlet oxygen, yielding ground state oxygen alongside astaxanthin in a triplet-excited state (). As a carotenoid, astaxanthin is then able to dissipate this energy by interacting with surrounding solvent, returning back to the ground state structurally intact, ready to participate in further quenching cycles (, ). Additionally, astaxanthin is also able to scavenge and thus deactivate peroxyl radical intermediates, a function likely dependent upon the formation of resonance stabilized, carbon-centered radical adducts (, ). As such, an ability for astaxanthin to extensively protect lipid-rich structures against peroxidation during periods of oxidative stress has been suggested (, , , ).
Research utilizing animal models have also identified a potential for astaxanthin to indirectly modulate the endogenous antioxidant defense system through interacting with redox sensitive transcription factors, such as nuclear factor erythroid 2-related factor 2 (Nrf2) (, ). At rest, Nrf2 is sequestered in the cytosol by Kelch-like ECH-associated protein 1 (Keap1); however, during periods of oxidative stress, modifications to cysteine residues on Keap1 cause Nrf2 to be released and translocated to nucleus where it binds to the antioxidant response element (ARE) (, ). Once activated, the Nrf2āARE signaling pathway initiates the transcription of several cytoprotective genes and enzymes capable of upregulating the endogenous antioxidant response to an oxidative stressor, potentially implicating Nrf2 in the beneficial effects of exercise (). Similarly, phytochemicals can also stimulate the activation of the Nrf2āARE pathway, a process which may occur through the modification of different cysteine residues to those targeted through exercise, suggesting a potential synergism between exercise and phytochemicals in the upregulation of antioxidant defense (). Although a specific mechanism of action has yet to be elucidated, research conducted in animal models report increases in Nrf2 expression, alongside the upregulation of endogenous antioxidant enzymes, including superoxide dismutase, catalase and glutathione peroxidase, following astaxanthin administration (, , ). As key components of the endogenous antioxidant defense system (), it is plausible that astaxanthin could activate endogenous antioxidant defense pathways upon administration. Future research is therefore required to investigate this mechanism further, including the interaction between astaxanthin and Nrf2 in exercising humans.
Safety of Astaxanthin Supplementation
In 2014, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) advocated an ADI of 0.034āmgĀ·kgā1Ā·dayā1 astaxanthin (2.38āmgĀ·dayā1 in a 70ākg human) based upon research previously conducted in rats (). This was later reiterated by an EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), where it was concluded that the safety of 4āmgĀ·dayā1 astaxanthin (~0.06āmgĀ·kgā1Ā·dayā1) had yet to be fully established (). In contrast, no adverse effects were reported in blood pressure or biochemical parameters, including a metabolic panel and cell blood count, in 19 healthy participants supplementing with 6āmgĀ·dayā1 astaxanthin for 8āweeks (). Similarly, no adverse effects were also reported in a recent exercise study where 16 trained individuals supplemented with 20āmgĀ·dayā1 astaxanthin for 4āweeks (). The acute intake of 40āmg astaxanthin has also been reported as āwell toleratedā in 32 healthy participants with only three mild events in the form of headaches reported in the 48āh post-intake (). This was, however, in response to a single dose, with information concerning the chronic intake of 40āmgĀ·dayā1 not currently available in a healthy adult cohort. Nevertheless, the chronic intake of 16āmgĀ·dayā1 and 40āmgĀ·dayā1 astaxanthin has been suggested as safe in patients suffering with functional dyspepsia (). One hundred and 31 patients were recruited and randomly assigned either 16āmgĀ·dayā1 astaxanthin (nā=ā43), 40āmgĀ·dayā1 astaxanthin (nā=ā44), or an appearance-matched control (nā=ā44) for 4āweeks. Although 36 adverse events were reported during supplementation and a 4āweek follow-up, prevalence was not significantly different between groups (16āmgĀ·dayā1: 15 adverse events in 10 patients vs. 40āmgĀ·dayā1: 8 adverse events in 7 patients vs. control: 13 adverse events in 7 patients) suggesting safety (). As a result, it may be possible to advocate both acute and chronic intakes of astaxanthin that are considerably greater than the current ADI (~2.38āmgĀ·dayā1). Future research is therefore required to further elucidate the safety of astaxanthin so that human consumption guidelines can be adjusted accordingly.
Astaxanthin and Exercise Metabolism
The metabolism of fat as an energy source is dependent upon the entry of long-chain fatty acids into the mitochondria; a process requiring the mitochondrial carnitine palmitoyltransferase (CPT) complex and in particular the CPT1 regulatory enzyme (). During exercise, RONS-induced oxidative damage to CPT1 can alter its function, attenuating the transportation of long-chain fatty acids and consequently limiting the ability for fats to be oxidized as a viable energy source (). Due to its lipophilic properties, astaxanthin is known to accumulate in the mitochondrial membrane following consumption and provide a protection against RONS-induced detriments to its function (, ). It has, therefore, been hypothesized that through its function as an antioxidant, astaxanthin could protect CPT1 against RONS-induced oxidative modifications, causing an indirect enhancement of exercising fat metabolism in the process ().
Aoi et al. () investigated this hypothesis with the use of an exercising mouse-model. In comparison to the control, 4āweeks of astaxanthin supplementation (0.02% wĀ·wā1 per 100āg of total dietary intake) enhanced the coimmunoprecipitation of fatty acid translocase (FAT)/CD36 and CPT1 by 14.5% (pā<ā0.05) due to a concomitant 41.4% decrease in the oxidative modification of CPT1 (pā<ā0.05). Muscle glycogen concentrations were also significantly greater in the astaxanthin group (2.7ā±ā0.1āmgĀ·gā1 tissue) in comparison to the control (2.3ā±ā0.1āmgĀ·gā1 tissue) and plasma non-esterified fatty acid (NEFA) concentrations tended to be higher (astaxanthin group: 1.05ā±ā0.05 mEqĀ·Lā1 vs. control group: 0.94ā±ā0.05 mEqĀ·Lā1), suggesting a potential glycogen sparing effect (). In a separate cohort of mice undertaking the same supplementation protocol, the respiratory exchange ratio (RER) was significantly lower from 20āmin onward during a 60āmin run (25āmĀ·minā1), with corresponding measures of fat oxidation (mgĀ·kgā1Ā·minā1) also 21% higher (pā<ā0.05) and carbohydrate oxidation (mgĀ·kgā1Ā·minā1) 12% lower (pā<ā0.05) in comparison to the control (). As a result, it was concluded that the antioxidant potential of astaxanthin is able to indirectly enhance the utilization of fats during exercise through increasing the intercalation of FAT/CD36 and CPT1 on the mitochondrial membrane (). Similar findings are also reported in a swimming mouse-model (). On completion of a 15āmin swim against an additional 5% body mass, mice supplemented with 6 and 30āmgĀ·kgā1 astaxanthin for 3āweeks had significantly greater plasma glucose concentrations (6āmgĀ·kgā1: 124āmgĀ·dLā1 vs. 30āmgĀ·kgā1: 135āmgĀ·dLā1 vs. control: 104āmgĀ·dLā1), with plasma NEFA also significantly elevated throughout exercise in the 30āmgĀ·kgā1 astaxanthin group. Muscle glycogen concentrations were also significantly greater post-exercise following 5āweeks of supplementation with 6 and 30āmgĀ·kgā1 astaxanthin (6āmgĀ·kgā1 group: 4.0āmgĀ·gā1 vs. 30āmgĀ·kgā1 group: 4.2āmgĀ·gā1 vs. control group: 3.4āmgĀ·gā1), with liver glycogen concentration also significantly greater in the 30āmgĀ·kgā1 group (30āmgĀ·kgā1: 49.8āmgĀ·gā1 vs. control: 40.7āmgĀ·gā1). In contrast, however, a significant decrement in plasma NEFA concentration has been reported post-exercise (30āmin run at 25āmĀ·minā1) in mice supplemented with 0.02 wĀ·wā1 astaxanthin for 2āweeks (astaxanthin group: 905ā±ā41āmEqĀ·Lā1 vs. control group: 1,151ā±ā61āmEqĀ·Lā1) (). Although the authors speculated that this resulted from an increased utilization within the skeletal muscle, no direct measurement was made (). Furthermore, despite a tendency for plasma glucose to be higher post-exercise in the astaxanthin group (astaxanthin group: 121ā±ā2āmgĀ·dLā1 vs. control group: 112ā±ā3āmgĀ·dLā1), a significant supplement effect was not reported, suggesting that astaxanthin did not exert a glycogen-sparing effect ().
Evidence from exercising mice models would therefore suggest that 3ā5āweeks of astaxanthin supplementation potentially exerts a metabolic benefit through enhancing fat utilization and attenuating muscle glycogen depletion during endurance-type exercise (, ). It should, however, be noted that outcomes reported in an animal model are not always replicable in a human model (). Interestingly, a similar metabolic effect has yet to be replicated within an exercising human cohort (, ). Four weeks of 4āmgĀ·dayā1 astaxanthin supplementation, for example, did not influence parameters of substrate metabolism (such as RER, carbohydrate and fat oxidation rates, and plasma glucose and NEFA concentrations) obtained during 2āh of submaximal cycling (5% below lactate threshold) in amateur endurance-trained males (nā=ā14; O2max ā„50āmLĀ·kgā1Ā·minā1) (). The 4āmgĀ·dayā1 dose issued, however, was trivial in comparison to the 6ā30āmgĀ·kgā1 doses that have been previously prescribed in a mouse-model (). To elicit a similar metabolic modulation as previously reported in a mouse-model, it was therefore hypothesized that a dose greater than 4āmgĀ·dayā1 would be required in an exercising human cohort (). As a result, Res et al. () recruited trained male cyclists or triathletes (O2peak:ā60ā±ā1āmLĀ·kgā1Ā·minā1) to a 4āweek supplementation protocol consisting of either 20āmgĀ·dayā1 astaxanthin, or an appearance-matched control in a double-blind, parallel design (nā=ā16 astaxanthin group; nā=ā15 control group). Despite a fivefold increase in dose, however, measures of RER, carbohydrate and fat oxidation rates, and concentrations of plasma glucose and free fatty acids were again not significantly affected during the completion of a 1āh steady-state cycle (50% Wmax) (). Based upon this evidence, it would therefore appear that 4āweeks of astaxanthin supplementation does not exert a metabolic effect during endurance exercise, even at greater levels of intake, in exercising humans.
Res et al. () also detected no measurable changes in the plasma concentrations of the lipid peroxide malondialdehyde (MDA) during exercise, suggesting an antioxidant effect of astaxanthin was not present. Although speculative, this observation may provide an insight as to why a metabolic effect was not reported in this study, with previous research suggesting that an indirect metabolic modulation is mediated through a protection of CPT1 from astaxanthin (). The lack of a direct antioxidant effect and the corresponding metabolic effect, reported by Res et al. (), may be attributable to either the high training and fitness demographics of the participants recruited (O2peak: 60ā±ā1āmLĀ·kgā1Ā·minā1; training frequency: >3 sessionsĀ·weekā1 for ā„2āyears) or the length of the supplementation period undertaken within this study (). Concentrations of MDA, for example, were reported to decrease significantly in sedentary individuals following 20āmgĀ·dayā1 astaxanthin for both 8 (astaxanthin group: 1.72ā±ā0.28āµmolĀ·Lā1 vs. control group: 2.08ā±ā0.12āµmolĀ·Lā1) and 12āweeks (astaxanthin group: 1.42ā±ā0.29āµmolĀ·Lā1 vs. control group: 2.00ā±ā0.24āµmolĀ·Lā1), respectively (). Likewise, 12 weeks of 8āmgĀ·dayā1 astaxanthin supplementation was also reported to attenuate markers of lipid peroxidation in healthy untrained males (), suggesting that the demographics of participants may be a confounding variable for the antioxidant action of astaxanthin. Furthermore, the rate at which fat is oxidized during exercise is also subject to large inter-individual variations, even at the same absolute and relative intensities (ā). The exercise intensity at which fat oxidation is maximal (FATmax) is again highly variable between individuals (, ). In 300 healthy men and women, for example, FATmax values in the range of 25 and 77% O2max were reported despite an average value of 48ā±ā1% O2max reported overall (). Consequently, if fat oxidation is measured at a constant steady-state intensity, the ability to determine the true effect of a nutritional intervention may be diminished as some individuals will be exercising above and others below the exercise intensity at which FATmax is elicited. Future research should consider participant demographics, such as training status, the supplementation protocols administered, as well as incorporating sensitive measurements of exercising substrate utilization. This may include employing an experimental protocol capable of detecting changes in metabolism across a range of exercise intensities (, ), so that the metabolic effect of astaxanthin can be explored in more depth in exercising humans.
Astaxanthin and Exercise Performance
During endurance exercise, the depletion of muscle glycogen is commonly reported in the etiology of fatigue; as such, methods aimed at attenuating this depletion, may provide an ergogenic benefit through delaying fatigue onset (). A metabolic mechanism that could potentially convey this benefit is the utilization of fat as an alternative energy source to glycogen during exercise (). With previous research conducted in mice illustrating such a metabolic effect (, ), a potential for astaxanthin to act as an ergogenic aid during the performance of endurance exercise has been hypothesized (ā, ).
Ikeuchi et al. () conducted a series of experiments in mice to investigate the ergogenic potential of astaxanthin (1.2, 6, or 30āmgĀ·kgā1) on swim time to exhaustion (TTE). In the first experiment, mice undertook a weekly swim TTE against an additional 10% body mass over a 5āweek supplementation period. In comparison to the control, a continuous significant improvement in TTE was observed from the first week onward in the mice supplemented with 6 (pā<ā0.01) and 30āmgĀ·kgā1 (pā<ā0.05) astaxanthin. After 5āweeks, this significant improvement was observed in a dose-dependent manner across all astaxanthin groups with an ergogenic benefit also reported in the 1.2āmgĀ·kgā1 astaxanthin group (1.2āmgĀ·kgā1 group: 2.27āmin vs. 6āmgĀ·kgā1 group: 3.32āmin vs. 30āmgĀ·kgā1 group: 5.12āmin vs. control group: 1.44āmin) (). Similar results were also reported in a separate cohort of mice, as 3āweeks of 6 and 30āmgĀ·kgā1 astaxanthin supplementation significantly improved swim TTE against an additional 5% body mass (6āmgĀ·kgā1 group: 27.50ā±ā3.04āmin vs. 30āmgĀ·kgā1 group: 36.06ā±ā4.13āmin vs. control group: 19.45ā±ā2.02āmin) (). Further support is also evident from a running mouse-model, as mice fed daily with 0.02 wĀ·wā1 astaxanthin for 4āweeks were able to significantly enhance TTE at a running intensity of 30āmĀ·minā1 by 34% (67.53ā±ā4.20āmin) in comparison to the exercising control (50.40ā±ā5.00āmin) ().
Based upon in vivo work conducted in mice, it therefore appears that astaxanthin is able to exert an ergogenic benefit during the performance of endurance exercise; an ability attributed to its aforementioned effect on substrate metabolism (, ). In humans, a similar ergogenic benefit was reported in amateur trained male cyclists (nā=ā14; O2maxā>ā50āmLĀ·kgā1Ā·minā1; weekly cycling volumeā>ā160ākmĀ·weekā1), as 4āweeks of astaxanthin supplementation (4āmgĀ·dayā1) significantly improved 20ākm cycling time trial (TT) performance when compared to baseline (baseline: 2,387ā±ā206ās vs. 4āweeks: 2,266ā±ā190ās) (). Furthermore, the 121ās time improvement (5%) reported in the astaxanthin group was also significantly greater than the corresponding 18ās improvement (<1%) reported in the control (baseline: 2,251ā±ā260ās vs. 4āweeks: 2,233ā±ā283ās), suggesting a treatment effect was present (pā<ā0.05; effect size: 1.25) (). In contrast, an ergogenic benefit was not reported during a 1āh cycling TT in well-trained male cyclists or triathletes (nā=ā31; O2peak: 60ā±ā1āmLĀ·kgā1Ā·minā1; training frequency: >3 sessionsĀ·weekā1 for >2āyears) following a 4āweek supplementation with either 20āmgĀ·dayā1 astaxanthin (baseline: 60.38ā±ā1.20āmin vs. 4āweeks: 59.14ā±ā1.21āmin) or an appearance-matched control (baseline: 59.43ā±ā1.37āmin vs. 4āweeks: 58.57ā±ā1.39āmin) (). Although there is no clear explanation for the disparity between the two findings, it should be noted that a metabolic mechanism was not reported by either study (, ). As the enhancement of fat metabolism and the subsequent sparing of muscle glycogen are the suggested mechanisms by which astaxanthin exerts its ergogenic potential, the absence of this effect may implicate an alternative ergogenic mechanism in Earnest et al. (), or partially explain the absence of a performance effect in Res et al. (). It is plausible, however, that the heterogeneity of the sample in Earnest et al. () may have contributed to the disparity reported between studies with regards to TT performance. Participants were randomly assigned to each treatment group and although a full familiarization was completed and baseline fitness characteristics appeared to be similar, the SD of each 20ākm TT (190ā283ās) was far greater than the 136ās time improvement reported in the astaxanthin group. To ensure the reliability of the performance outcome reported, the retest reliability of the 20ākm TT should have been reported. As this information is not available, it is difficult to conclude whether the time improvement reported in the astaxanthin group (5%) resulted from a significant supplement effect or the variation present in the study protocol. Previously, a coefficient of variation (CV) of 1.5% (1.1ā2.1%; ±10% confidence limits) has been reported for the performance of a 20ākm TT separated by 4āweeks in 19 competitive level cyclists (>2āyears racing experience at an A or B grade standard) (). If a similar retest reliability would have been reported by Earnest et al. (), the ergogenic effect of astaxanthin could have been inferred as the performance improvement during the 20ākm TT would have been greater than the CV reported. Future research should, therefore, seek to confirm whether an ergogenic potential of astaxanthin is present within an exercising human cohort, with a particular emphasis placed upon the reliability of testing protocols to ensure that a more robust conclusion can be made. In comparison to previous performance studies, future research should also consider implementing performance tests of a longer duration (>1āh), allowing the ergogenic potential of astaxanthin to be investigated during the completion of an exercise bout that may reflect the proposed mechanism of action more appropriately.
Astaxanthin and Exercise Recovery
The completion of vigorous intensity exercise training sessions and competitive events are known to increase numerous physiological stressors, such as muscle damage, oxidative stress and inflammation (). Detriments to the skeletal muscle observed in response to the completion of vigorous intensity exercise may, therefore, not only result from damage directly induced by RONS but also damage induced through the inflammatory cascade. If recovery is inadequate following exercise, it may prevent recreationally active individuals and athletes from completing the subsequent exercise training sessions required to drive adaptation and/or performance improvements. Inadequate recovery may also increase risks of injury, illness and overtraining (). As a result, the investigation of strategies that can reduce the negative effect of exercise-induced muscle damage and/or accelerate the recovery process has become increasingly popular (, ā).
Through its potency as an antioxidant compound, it is plausible to propose that astaxanthin could exert a recovery benefit through the inhibition of both pro-oxidant and pro-inflammatory intermediates (, ). In vitro research has reported a dose-dependent inhibition of nitric oxide (NO) and intracellular RONS, as well as the hydrogen peroxide-induced activation of nuclear factor kappa B (NFĪŗB) following 5ā100āµM astaxanthin administration (). Furthermore, 50āµM astaxanthin also completely inhibited the stimulation of inducible nitric oxide synthase (iNOS) and iNOS mRNA. As iNOS is predominantly present in many inflammatory conditions (), the subsequent expression of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), were also significantly suppressed (TNF-α: ā76%; IL-1β: ā46%) in comparison to the control (). Investigation with in vivo mouse models also reported a similar effect following a lipopolysaccharide stressor, with significant reductions in plasma NO (ā58%), TNF-α (ā50%), and IL-1β (ā57%) reported following treatment with a 40āmgĀ·kgā1 dose of astaxanthin in comparison to the control (). Although the work of Lee et al. () was not specific to the recovery response to exercise per se, it displays a potential mechanism by which astaxanthin may promote recovery through inhibiting the oxidative and inflammatory responses to a physiological stressor. Supportive evidence is, however, received from an exercising mouse model (). Following a running TTE at an intensity of 28āmĀ·minā1, 3āweeks of astaxanthin supplementation (0.02 wĀ·wā1) attenuated oxidative damage to lipid and nucleic acid molecules in the skeletal and cardiac muscle tissue. This was evidenced by the substantial decrease of 4-hydroxy-2-nonenal (4-HNE) modified protein production, as well as the significant inhibition of 8-hydroxy-2ā²-deoxyguanosine (8-OHdG) in the skeletal (ā12%) and cardiac (ā17%) muscle tissue, in comparison to the control (). Furthermore, 24āh post-exhaustive exercise, dietary astaxanthin also significantly decreased the activity of myeloperoxidase (MPO) by 50% in the skeletal muscle tissue and 33% in the cardiac muscle tissue in comparison to the control, as well as significantly reducing creatine kinase (CK) activity in the plasma (astaxanthin: 2,617 UĀ·Lā1 vs. control: 3,032 UĀ·Lā1) (). As MPO and CK are markers of the secondary neutrophil infiltration and muscle damage, this also highlights a potential for astaxanthin to attenuate the inflammatory muscle damage response in the days following exhaustive exercise.
The use of in vitro and in vivo mouse-models have, therefore, demonstrated an ability of astaxanthin to inhibit a series of biomarkers linked to the onset of muscle damage, oxidative stress, and/or inflammation. As a result, research has subsequently aimed to elucidate whether astaxanthin supplementation possesses the ability to modulate the recovery response in an exercising human cohort. In a sample of 20 resistance-trained males, for example, recovery from a muscle damaging bout of eccentric exercise was quantified through perceptions of muscle soreness, concentrations of plasma CK and the recovery of one repetition maximum concentric strength, mean isometric force, and mean dynamic force (). Although a significant time effect for each measure was present in the 96āh post-exercise, a supplement effect of 4āmgĀ·dayā1 astaxanthin for 3āweeks prior to exercise was not observed. As young, resistance-trained males were recruited, however, it is uncertain as to whether this outcome could be generalized to less trained individuals or to those participating in events other than high force, resistance exercise. Future research should, therefore, aim to address this uncertainty by recruiting participants with different training demographics to investigate whether training status can confound the efficacy of astaxanthin as a recovery aid post-exercise. More recently, markers of muscle damage and oxidative stress were measured in response to a 2āh bout of soccer exercise in elite youth male soccer players (nā=ā32; age: 17ā18āyears) following supplementation with 4āmgĀ·dayā1 astaxanthin for 90ādays during the regular competitive season (). A supplement effect was not reported in exercise-induced changes in plasma CK and generic measures of oxidative stress (thiobarbituric acid-reactive substances, advanced oxidation protein products, superoxide anion, total antioxidant status, sulphydril groups, and superoxide dismutase), suggesting a recovery effect was not present (). The same research group later conducted a similar investigation in a separate cohort of elite youth male soccer players (nā=ā40; age: 17ā18āyears) during the competitive season (). Adherence to exercise training alone over the 90 day protocol was reported to significantly attenuate muscle damage, implicated by a reduction in both plasma CK (astaxanthin: ā44.6%; control: ā30.1%) and lactate dehydrogenase (LDH) (astaxanthin: ā27.4%; control: ā18.5%) from baseline measures. Astaxanthin supplementation (4āmgĀ·dayā1) was suggested to augment these reductions further, while also exerting a secondary anti-inflammatory effect through attenuating training-induced increases in serum C-reactive protein and total leukocyte and neutrophil counts, in comparison to the control (). Caution is required however, as a significant supplement effect of astaxanthin was not reported in regard to each of the aforementioned measures, apart from the LDH biomarker (pā<ā0.05); suggesting that astaxanthin actually had little effect. Furthermore, when attempting to elucidate the effect of astaxanthin on muscle damage and recovery responses to exercise, both Djordjevic et al. () and Baralic et al. () placed a heavy reliance upon indirect biomarkers such as CK and/or LDH obtained from the blood. Both CK and LDH have been reported to possess a large inter-individual variance and low reliability in blood concentrations (), with the use of muscular force production purported to be a more reliable marker of skeletal muscle injury (, ). Future research should, therefore, be conducted with the use of suitable analytical methods so that a more comprehensive conclusion can be made regarding astaxanthin and the attenuation of exercise-induced muscle damage in exercising humans.
Conclusion
Previous research conducted in both in vitro cell-cultures and in vivo animal models provide evidence to support the use of astaxanthin as a dietary supplement for recreationally active individuals and athletes. According to these models, exercise metabolism, performance and recovery is improved following 3ā5āweeks of intake; with each function attributed in part to the potent antioxidant capacity of this xanthophyll carotenoid. In contrast, the current efficacy surrounding astaxanthin supplementation in exercising humans is somewhat equivocal. This is evidenced by the limited number of well-controlled scientific investigations in this research area. Future research is therefore required with a particular emphasis placed upon scientific rigor and contemporary considerations of the most appropriate methodological and analytical strategies. Only once this has been achieved can a more robust conclusion be made about the application of astaxanthin as a dietary supplement for exercising humans.
Statements
Author contributions
DB, SAS, and LM originally conceived the idea for this review, and DB took overall responsibility for synthesizing the literature and drafting the manuscript. Ongoing critical input was received from LG, SD, SAS, and LM. All authors read and approved the final manuscript.
Conflict of interest
SAS and LM have a professional relationship with AstaRealĀ®. DB has received external research funding from AstaRealĀ® to undertake postgraduate study. LG and SD have no professional relationship with AstaRealĀ® and have no conflict of interest.
References
1
BussoT. Variable dose-response relationship between exercise training and performance. Med Sci Sports Exerc (2003) 35(7):1188ā95.10.1249/01.MSS.0000074465.13621.37
2
RadakZZhaoZKoltaiEOhnoHAtalayM. Oxygen consumption and usage during physical exercise: the balance between oxidative stress and ROS-dependent adaptive signaling. Antioxid Redox Signal (2013) 18(10):1208ā46.10.1089/ars.2011.4498
3
RadakZIshiharaKTekusEVargaCPosaABaloghLet alExercise, oxidants, and antioxidants change the shape of the bell-shaped hormesis curve. Redox Biol (2017) 12:285ā90.10.1016/j.redox.2017.02.015
4
PowersSKJacksonMJ. Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. Physiol Rev (2008) 88(4):1243ā76.10.1152/physrev.00031.2007
5
BastAHaenenGRMM. Nutritional antioxidants: it is time to categorise. Antioxidants in Sport Nutrition. (2015). Available from: http://www.ncbi.nlm.nih.gov/pubmed/26065087
6
WagnerKH. Antioxidants in sport nutrition: all the same effectiveness? In: LamprechtM, editor. Antioxidants in Sport Nutrition. Boca Raton, FL: CRC Press/Taylor & Francis (2015). 4 p.
7
PingitoreALimaGPMastorciFQuinonesAIervasiGVassalleC. Exercise and oxidative stress: potential effects of antioxidant dietary strategies in sports. Nutrition (2015) 31(7ā8):916ā22.10.1016/j.nut.2015.02.005
8
Dalle-DonneIRossiRColomboRGiustariniDMilzaniA. Biomarkers of oxidative damage in human disease. Clin Chem (2006) 52(4):601ā23.10.1373/clinchem.2005.061408
9
PeterneljTTCoombesJS. Antioxidant supplementation during exercise training: beneficial or detrimental?Sports Med (2011) 41(12):1043ā69.10.2165/11594400-000000000-00000
10
SlatteryKBentleyDCouttsAJ. The role of oxidative, inflammatory and neuroendocrinological systems during exercise stress in athletes: implications of antioxidant supplementation on physiological adaptation during intensified physical training. Sports Med (2015) 45(4):453ā71.10.1007/s40279-014-0282-7
11
AoiWNaitoYSakumaKKuchideMTokudaHMaokaTet alAstaxanthin limits exercise-induced skeletal and cardiac muscle damage in mice. Antioxid Redox Signal (2003) 5(1):139ā44.10.1089/152308603321223630
12
IkeuchiMKoyamaTTakahashiJYazawaK. Effects of astaxanthin supplementation on exercise-induced fatigue in mice. Biol Pharm Bull (2006) 29(10):2106ā10.10.1248/bpb.29.2106
13
AoiWNaitoYTakanamiYIshiiTKawaiYAkagiriSet alAstaxanthin improves muscle lipid metabolism in exercise via inhibitory effect of oxidative CPT I modification. Biochem Biophys Res Commun (2008) 366(4):892ā7.10.1016/j.bbrc.2007.12.019
14
EarnestCPLupoMWhiteKMChurchTS. Effect of astaxanthin on cycling time trial performance. Int J Sports Med (2011) 32(11):882ā8.10.1055/s-0031-1280779
15
LiuPHAoiWTakamiMTerajimaHTanimuraYNaitoYet alThe astaxanthin-induced improvement in lipid metabolism during exercise is mediated by a PGC-1α increase in skeletal muscle. J Clin Biochem Nutr (2014) 54(2):86ā9.10.3164/jcbn.13-110
16
GuerinMHuntleyMOlaizolaM. Haematococcus astaxanthin: applications for human health and nutrition. Trends Biotechnol (2003) 21(5):210ā6.10.1016/S0167-7799(03)00078-7
17
HusseinGSankawaUGotoHMatsumotoKWatanabeH. Astaxanthin, a carotenoid with potential in human health and nutrition. J Nat Prod (2006) 69(3):443ā9.10.1021/np050354+
18
AmbatiRMoiPRaviSAswathanarayanaR. Astaxanthin: sources, extraction, stability, biological activities and its commercial applications ā a review. Mar Drugs (2014) 12(1):128ā52.10.3390/md12010128
19
KurashigeMOkimasuEInoueMUtsumiK. Inhibition of oxidative injury of biological membranes by astaxanthin. Physiol Chem Phys Med NMR (1990) 22(1):27ā38.
20
MikiW. Biological functions and activities of animal carotenoids. Pure Appl Chem (1991) 63(1):141ā6.10.1351/pac199163010141
21
VisioliFArtariaC. Astaxanthin in cardiovascular health and disease: mechanisms of action, therapeutic merits, and knowledge gaps. Food Funct (2017) 8(1):39ā63.10.1039/C6FO01721E
22
GotoSKogureKAbeKKimataYKitahamaKYamashitaEet alEfficient radical trapping at the surface and inside the phospholipid membrane is responsible for highly potent antiperoxidative activity of the carotenoid astaxanthin. Biochim Biophys Acta (2001) 1512(2):251ā8.10.1016/S0005-2736(01)00326-1
23
EFSA FEEDAP Panel. Opinion of the scientific panel on additives and products or substances used in animal feed (FEEDAP) on the safety of use of colouring agents in animal nutrition ā PART I. General principles and astaxanthin. EFSA J (2005) 3(12):291.10.2903/j.efsa.2005.291
24
EFSA NDA Panel. Scientific opinion on the safety of astaxanthin-rich ingredients (AstaREAL A1010 and AstaREAL L10) as novel food ingredients EFSA panel on dietetic products, nutrition and allergies (NDA). EFSA J (2014) 12:1ā35.10.2903/j.efsa.2014.3757
25
ShahMMLiangYChengJJDarochM. Astaxanthin-producing green microalga Haematococcus pluvialis: from single cell to high value commercial products. Front Plant Sci (2016) 7:531.10.3389/fpls.2016.00531
26
ĆsterlieMBjerkengBLiaaen-JensenS. Plasma appearance and distribution of astaxanthin E/Z and R/S isomers in plasma lipoproteins of men after single dose administration of astaxanthin. J Nutr Biochem (2000) 11(10):482ā90.10.1016/S0955-2863(00)00104-2
27
Mercke OdebergJLignellAPetterssonAHƶglundP. Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. Eur J Pharm Sci (2003) 19(4):299ā304.10.1016/S0928-0987(03)00135-0
28
Coral-HinostrozaGNYtrestĆøylTRuyterBBjerkengB. Plasma appearance of unesterified astaxanthin geometrical E/Z and optical R/S isomers in men given single doses of a mixture of optical 3 and 3ā²R/S isomers of astaxanthin fatty acyl diesters. Comp Biochem Physiol C Toxicol Pharmacol (2004) 139(1ā3):99ā110.10.1016/j.cca.2004.09.011
29
RüferCEMoesenederJBrivibaKRechkemmerGBubA. Bioavailability of astaxanthin stereoisomers from wild (Oncorhynchus Spp.) and aquacultured (Salmo salar) salmon in healthy men: a randomised, double-blind study. Br J Nutr (2008) 99(5):1048ā54.10.1017/S0007114507845521
30
EFSA FEEDAP Panel. Scientific opinion on the safety and efficacy of synthetic astaxanthin as feed additive for salmon and trout, other fish, ornamental fish, crustaceans and ornamental birds. EFSA J (2014) 12(6):3724.10.2903/j.efsa.2014.3724
31
OkadaYIshikuraMMaokaT. Bioavailability of astaxanthin in Haematococcus algal extract: the effects of timing of diet and smoking habits. Biosci Biotechnol Biochem (2009) 73(9):1928ā32.10.1271/bbb.90078
32
ShimidzuNGotoMMikiW. Carotenoids as singlet oxygen quenchers in marine organisms. Fish Sci (1996) 62(1):134ā7.10.2331/FISHSCI.62.134
33
StahlWSiesH. Antioxidant activity of carotenoids. Mol Aspects Med (2003) 24(6):345ā51.10.1016/S0098-2997(03)00030-X
34
PalozzaPKrinskyNI. Astaxanthin and canthaxanthin are potent antioxidants in a membrane model. Arch Biochem Biophys (1992) 297(2):291ā5.10.1016/0003-9861(92)90675-M
35
NaguibYM. Antioxidant activities of astaxanthin and related carotenoids. J Agric Food Chem (2000) 48(4):1150ā4.10.1021/jf991106k
36
YangYSeoJMNguyenAPhamTXParkHJParkYet alAstaxanthin-rich extract from the green alga Haematococcus pluvialis lowers plasma lipid concentrations and enhances antioxidant defense in apolipoprotein E knockout mice. J Nutr (2011) 141(9):1611ā7.10.3945/jn.111.142109
37
YangYPhamTXWegnerCJKimBKuCSParkYKet alAstaxanthin lowers plasma TAG concentrations and increases hepatic antioxidant gene expression in diet-induced obesity mice. Br J Nutr (2014) 112(11):1797ā804.10.1017/S0007114514002554
38
KasparJWNitureSKJaiswalAK. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med (2009) 47(9):1304ā9.10.1016/j.freeradbiomed.2009.07.035
39
DoneAJTraustadóttirT. Nrf2 mediates redox adaptations to exercise. Redox Biol (2016) 10:191ā9.10.1016/j.redox.2016.10.003
40
XuJRongSGaoHChenCYangWDengQet alA combination of flaxseed oil and astaxanthin improves hepatic lipid accumulation and reduces oxidative stress in high fat-diet fed rats. Nutrients (2017) 9(3):E271.10.3390/nu9030271
41
PowersSKJiLLKavazisANJacksonMJ. Reactive oxygen species: impact on skeletal muscle. Compr Physiol (2011) 1(2):941ā69.10.1002/cphy.c100054
42
SpillerGADewellA. Safety of an astaxanthin-rich Haematococcus pluvialis algal extract: a randomized clinical trial. J Med Food (2003) 6(1):51ā6.10.1089/109662003765184741
43
ResPTCermakNMStinkensRTollaksonTJHaenenGRBastAet alAstaxanthin supplementation does not augment fat use or improve endurance performance. Med Sci Sports Exerc (2013) 45(6):1158ā65.10.1249/MSS.0b013e31827fddc4
44
KupcinskasLLafoliePLignellĆ KiudelisGJonaitisLAdamonisKet alEfficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without helicobacter pylori infection: a prospective, randomized, double blind, and placebo-controlled study. Phytomedicine (2008) 15(6ā7):391ā9.10.1016/j.phymed.2008.04.004
45
YeoWKCareyALBurkeLSprietLLHawleyJA. Fat adaptation in well-trained athletes: effects on cell metabolism. Appl Physiol Nutr Metab (2011) 36(1):12ā22.10.1139/H10-089
46
WolfAMAsohSHiranumaHOhsawaIIioKSatouAet alAstaxanthin protects mitochondrial redox state and functional integrity against oxidative stress. J Nutr Biochem (2010) 21(5):381ā9.10.1016/j.jnutbio.2009.01.011
47
KiddP. Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Altern Med Rev (2011) 16(4):355ā64.
48
ShanksNGreekRGreekJ. Are animal models predictive for humans?Philos Ethics Humanit Med (2009) 4:2.10.1186/1747-5341-4-2
49
ChoiHDYounYKShinWG. Positive effects of astaxanthin on lipid profiles and oxidative stress in overweight subjects. Plant Foods Hum Nutr (2011) 66(4):363ā9.10.1007/s11130-011-0258-9
50
KarppiJRissanenTHNyyssƶnenKKaikkonenJOlssonAGVoutilainenSet alEffects of astaxanthin supplementation on lipid peroxidation. Int J Vitam Nutr Res (2007) 77(1):3ā11.10.1024/0300-9831.77.1.3
51
GoedeckeJHSt Clair GibsonAGroblerLCollinsMNoakesTDLambertEV. Determinants of the variability in respiratory exchange ratio at rest and during exercise in trained athletes. Am J Physiol Endocrinol Metab (2000) 279(6):E1325ā34.10.1152/ajpendo.2000.279.6.E1325
52
AchtenJGleesonMJeukendrupAE. Determination of the exercise intensity that elicits maximal fat oxidation. Med Sci Sports Exerc (2002) 34(1):92ā7.10.1097/00005768-200201000-00015
53
VenablesMCAchtenJJeukendrupAE. Determinants of fat oxidation during exercise in healthy men and women: a cross-sectional study. J Appl Physiol (2005) 98(1):160ā7.10.1152/japplphysiol.00662.2003
54
CoyleEFCogganARHemmertMKIvyJL. Muscle glycogen utilization during prolonged strenuous exercise when fed carbohydrate. J Appl Physiol (1986) 61(1):165ā72.10.1152/jappl.1986.61.1.165
55
ClarkBClarkBPatonCDOāBrienBJ. The reliability of performance during computer-simulated varying gradient cycling time trials. J Sci Cycling (2014) 3. Available from: http://www.jsc-journal.com/ojs/index.php?journal=JSC&page=article&op=view&path[]=75
56
LeederJGissaneCvan SomerenKGregsonWHowatsonG. Cold water immersion and recovery from strenuous exercise: a meta-analysis. Br J Sports Med (2012) 46(4):233ā40.10.1136/bjsports-2011-090061
57
RobertsLANosakaKCoombesJSPeakeJM. Cold water immersion enhances recovery of submaximal muscle function after resistance exercise. Am J Physiol Regul Integr Comp Physiol (2014) 307(8):R998ā1008.10.1152/ajpregu.00180.2014
58
ConnollyDAJSayersSPMcHughMP. Treatment and prevention of delayed onset muscle soreness. J Strength Cond Res (2003) 17(1):197ā208.10.1519/00124278-200302000-00030
59
HowatsonGvan SomerenKA. The prevention and treatment of exercise-induced muscle damage. Sports Med (2008) 38(6):483ā503.10.2165/00007256-200838060-00004
60
HillJHowatsonGvan SomerenKLeederJPedlarC. Compression garments and recovery from exercise-induced muscle damage: a meta-analysis. Br J Sports Med (2014) 48(18):1340ā6.10.1136/bjsports-2013-092456
61
LeeSJBaiSKLeeKSNamkoongSNaHJHaKSet alAstaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol Cells (2003) 16(1):97ā105.
62
ReidM. Reactive oxygen species as agents of fatigue. Med Sci Sports Exerc (2016) 48(11):2239ā46.10.1249/MSS.0000000000001006
63
BloomerRJFryASchillingBChiuLHoriNWeissL. Astaxanthin supplementation does not attenuate muscle injury following eccentric exercise in resistance-trained men. Int J Sport Nutr Exerc Metab (2005) 15(4):401ā12.10.1123/ijsnem.15.4.401
64
DjordjevicBBaralicIKotur-StevuljevicJStefanovicAIvanisevicJRadivojevicNet alEffect of astaxanthin supplementation on muscle damage and oxidative stress markers in elite young soccer players. J Sports Med Phys Fitness (2012) 52(4):382ā92.
65
BaralicIAndjelkovicMDjordjevicBDikicNRadivojevicNSuzin-ZivkovicVet alEffect of astaxanthin supplementation on salivary IgA, oxidative stress, and inflammation in young soccer players. Evid Based Complement Alternat Med (2015) 2015:1ā9.10.1155/2015/783761
66
WarrenGLLoweDAArmstrongRB. Measurement tools used in the study of eccentric contraction-induced injury. Sports Med (1999) 27(1):43ā59.10.2165/00007256-199927010-00004
Summary
Keywords
antioxidants, carotenoids, Haematococcus pluvialis, oxidative stress, inflammation, delayed onset muscle soreness, fat oxidation, endurance exercise
Citation
Brown DR, Gough LA, Deb SK, Sparks SA and McNaughton LR (2018) Astaxanthin in Exercise Metabolism, Performance and Recovery: A Review. Front. Nutr. 4:76. doi: 10.3389/fnut.2017.00076
Received
27 October 2017
Accepted
26 December 2017
Published
18 January 2018
Volume
4 - 2017
Edited by
Bruno Gualano, University of SĆ£o Paulo, Brazil
Reviewed by
Luigi Iuliano, Sapienza UniversitĆ di Roma, Italy; Roger Hurst, The New Zealand Institute for Plant & Food Research Ltd., New Zealand
Updates
Copyright
Ā© 2018 Brown, Gough, Deb, Sparks and McNaughton.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: S. Andy Sparks, sparksa@edgehill.ac.uk
Specialty section: This article was submitted to Sport and Exercise Nutrition, a section of the journal Frontiers in Nutrition
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.